Home›Clinical trials›The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help women going through menopause lose weight.

Recruiting now. Registry record last updated August 18, 2026.

Who can join
Adults 46 to 60, women only, have obesity, BMI 27+.
What you take
Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The study runs about 17 months.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Phase 4Sponsor Mayo ClinicDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 40

What this study is for

Primary condition: Obesity. Also studied in: Menopause Hot Flashes.

Full scientific study title: The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity.

Who can join

Age46 to 60SexFemaleBMI27 or higher

Adults 46 to 60, women only, have obesity, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Females
  • Age 46-60 years old.
  • BMI ≥30 kg/m2 or BMI ≥27 kg/m2 in the presence of adiposity-associated diseases (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
  • Presence of bothersome hot flashes (an average of ≥ 28 episodes during a consecutive 2-week period with symptom severity sufficient to have prompted the participant to seek therapeutic treatment).
  • Hot flashes must be present for \>30 days prior to study entry.

Key exclusion criteria

  • Current or recent use (past 4 weeks) treatment with menopausal hormone therapy.
  • Any current, recent use (past 4 weeks), or planned use of:
  • Estrogen-containing contraceptive methods or menopausal hormone therapy (oral, transdermal, high dose vaginal ring, injection, pellets).
  • Vaginal estrogen.
  • Androgens.

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Florida1 site

Timeline

Started enrolling: April 8, 2026. Expected completion: September 18, 2027. Last updated on ClinicalTrials.gov: August 18, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.